A Phase 2 interventional study of teprotumumab and normal saline in Thyroid Associated Ophthalmopathies and Thyroid-Associated Ophthalmopathy, sponsored by Amgen. Completed at 15 sites in 4 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2024-12-17.
Sponsored by Amgen · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies testing teprotumumab in Graves Ophthalmopathy — 2 open to participants now, 3 under way, 1 of them phase 3. teprotumumab · Graves Ophthalmopathy.
Among the 12 studies testing teprotumumab in Graves Ophthalmopathy, this one is the 3rd largest by enrollment, is the only one that started in 2013, is one of 2 in phase 2, and was the 1st registered.
199 studies on the registry are indexed under Graves Ophthalmopathy; 58 are open to participants now.
Browse Graves Ophthalmopathy studies →2 of the 12 studies testing teprotumumab in Graves Ophthalmopathy are open now, in 1 country. Recruiting first, the newest first:
Sun Yat-sen University · Sites in China
Ages 18–65
Sheba Medical Center
Ages 18+
By country, each count listing its studies:
teprotumumab: first FDA approval 2020 (TEPEZZA), first EMA approval 2025. What it is approved for, and how studies give it, is on its page →
Of the 38 Graves Ophthalmopathy studies recruiting now, 8 (21%) set no upper age limit and 16 (42%) stop at 75 or younger; 1 takes children under 18; 9 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
First in 2013; this study’s year is marked. 1 started in 2013.
This study's enrollment of 88 is above the median of 63 across 146 interventional studies indexed under Graves Ophthalmopathy.
Median enrollment 56 across the 12 interventional studies. Of the 9 that completed or were terminated, 4 (44%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 12 have an industry lead sponsor. The 3 most frequent:
Amgen is the lead sponsor of 1,047 studies on the registry; 51 are open to participants now.
Of its 246 completed or terminated interventional studies of FDA-regulated products, 166 (67%) have results posted.
14 studies in Graves Ophthalmopathy by Amgen: 1 open now, 3 under way, 1 of them phase 3. Of 10 finished, 4 (40%) have results posted.
Among the 14 studies in Graves Ophthalmopathy by Amgen, this one is the 4th largest by enrollment of the 12 interventional ones that give a count, is the only one that started in 2013, is one of 2 in phase 2, and was the 1st registered.
Amgen’s Graves Ophthalmopathy studies by the year they started, since 2013.
None of the studies under way reaches primary completion within a year.
Among the 12 studies testing teprotumumab in Graves Ophthalmopathy, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Amgen’s 14 in Graves Ophthalmopathy:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The primary objective of this study is to investigate the efficacy, safety, and tolerability of RV 001 (teprotumumab), a fully human anti-IGF1R antibody, administered q3W for 6 months, in comparison to placebo, in the treatment of participants suffering from active TED.
"Funding Source - FDA OOPD"
Study with completed results acquired from Horizon in 2024.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A placebo infusion (normal saline) administered q3W by IV infusion over a period of 24 weeks for a total of 8 infusions.
Drug: normal saline
Teprotumumab administered q3W by IV infusion over a period of 24 weeks for a total of 8 infusions. All participants start treatment at a dose of 10 mg/kg. At Week 3, the dose is escalated to 20 mg/kg and kept constant for the remainder of the study.
Drug: teprotumumab
Also known as: RV 001, HZN-001
Responder Status at Week 24
Number of participants classified as responders and non-responders at Week 24. Responders were defined as participants with a reduction in clinical activity score (CAS, see Outcome Measure 4 description for details) of ≥ 2 points, and a reduction in proptosis (amount of protrusion of the eye from the orbital rim) of ≥ 2 mm in the study eye, and no deterioration (increase in CAS of ≥ 2 points or increase in proptosis of ≥ 2 mm) in the non-study eye. Participants who had no assessment at 24 weeks were considered non-responders.
Time frame: Week 24
Overall Average Change From Baseline in Graves' Ophthalmopathy Quality of Life (GO-QOL) Scale - Overall to Week 24 (Mixed-Model Repeated Measures [MMRM])
The GO-QOL is a 16-item self-administered questionnaire used to assess the perceived effects of thyroid eye disorder (TED) by the participants on their daily physical and psychosocial functioning. Two subscales of the 16-question GO-QOL have been defined: Visual Functioning and Appearance, with 8 questions comprising each subscale. The transformed overall score is the sum of scores from all 16 questions to a scale of 0 (worst health) to 100 (best health).
Time frame: Baseline to Week 24
Overall Average Change From Baseline in Proptosis of the Study Eye to Week 24 (MMRM)
Proptosis is the amount of protrusion of the eye from the orbital rim. Measurements were recorded using the Hertel exophthalmometer. Participants with a decrease ≥ 2 mm were considered improving, those with an increase or decrease \< 2 mm were considered remaining stable, and those with an increase ≥ 2 mm were considered worsening.
Time frame: Baseline to Week 24
Overall Average Change From Baseline in CAS to Week 24 (MMRM)
The 7-item European Group on Graves' Ophthalmopathy (EUGOGO) amended CAS was used to evaluate clinical activity. For each of the following items, one point is given: spontaneous orbital pain, gaze evoked orbital pain, eyelid swelling that is considered to be due to active (inflammatory phase) Graves' ophthalmopathy (GO), eyelid erythema, conjunctival redness that is considered to be due to active (inflammatory phase) GO, chemosis, and inflammation of caruncle or plica. The sum of these points is the total score, with 0 indicating no clinical activity and 7 indicating the most severe clinical activity.
Time frame: Baseline to Week 24
Overall Average Change From Baseline in GO-QOL Scale - Visual Functioning to Week 24 (MMRM)
The GO-QOL is a 16-item self-administered questionnaire used to assess the perceived effects of TED by the participants on their daily physical and psychosocial functioning. Two subscales of the 16-question GO-QOL have been defined: Visual Functioning and Appearance, with 8 questions comprising each subscale. Transformed Visual Functioning score is the sum of scores from following 8 questions to a scale of 0 (worst health) to 100 (best health): bicycling, driving, moving around the house, walking outdoors, reading, watching television (TV), hobby or pastime, feel hindered.
Time frame: Baseline to Week 24
Overall Average Change From Baseline in GO-QOL Scale - Appearance to Week 24 (MMRM)
The GO-QOL is a 16-item self-administered questionnaire used to assess the perceived effects of TED by the participants on their daily physical and psychosocial functioning. Two subscales of the 16-question GO-QOL have been defined: Visual Functioning and Appearance, with 8 questions comprising each subscale. Transformed Appearance score is the sum of scores from the following 8 questions to a scale of 0 (worst health) to 100 (best health): feel appearance has changed, feel being stared at, feel people react unpleasantly, influence on self-confidence, feel socially isolated, influence on making friends, appear less often on photos, try to mask changes in appearance.
Time frame: Baseline to Week 24
| Milestone | Placebo | Teprotumumab |
|---|---|---|
| Started | 45 | 42 |
| Completed | 38 | 36 |
| Not completed | 7 | 6 |
| Withdrew: Adverse event | 2 | 5 |
| Withdrew: Lack of efficacy | 2 | 0 |
| Withdrew: Other | 3 | 1 |
Number of participants classified as responders and non-responders at Week 24. Responders were defined as participants with a reduction in clinical activity score (CAS, see Outcome Measure 4 description for details) of ≥ 2 points, and a reduction in proptosis (amount of protrusion of the eye from the orbital rim) of ≥ 2 mm in the study eye, and no deterioration (increase in CAS of ≥ 2 points or increase in proptosis of ≥ 2 mm) in the non-study eye. Participants who had no assessment at 24 weeks were considered non-responders.
| Participants | Placebo | Teprotumumab |
|---|---|---|
| Responder | 9 | 29 |
| Non-Responder / Missing | 36 | 13 |
The GO-QOL is a 16-item self-administered questionnaire used to assess the perceived effects of thyroid eye disorder (TED) by the participants on their daily physical and psychosocial functioning. Two subscales of the 16-question GO-QOL have been defined: Visual Functioning and Appearance, with 8 questions comprising each subscale. The transformed overall score is the sum of scores from all 16 questions to a scale of 0 (worst health) to 100 (best health).
| units on a scale | Placebo | Teprotumumab |
|---|---|---|
| Overall Average Change From Baseline in Graves' Ophthalmopathy Quality of Life (GO-QOL) Scale - Overall to Week 24 (Mixed-Model Repeated Measures [MMRM]) | 6.77 ± 2.251 | 17.74 ± 2.423 |
Proptosis is the amount of protrusion of the eye from the orbital rim. Measurements were recorded using the Hertel exophthalmometer. Participants with a decrease ≥ 2 mm were considered improving, those with an increase or decrease \< 2 mm were considered remaining stable, and those with an increase ≥ 2 mm were considered worsening.
| mm | Placebo | Teprotumumab |
|---|---|---|
| Overall Average Change From Baseline in Proptosis of the Study Eye to Week 24 (MMRM) | -0.15 ± 0.188 | -2.46 ± 0.200 |
The 7-item European Group on Graves' Ophthalmopathy (EUGOGO) amended CAS was used to evaluate clinical activity. For each of the following items, one point is given: spontaneous orbital pain, gaze evoked orbital pain, eyelid swelling that is considered to be due to active (inflammatory phase) Graves' ophthalmopathy (GO), eyelid erythema, conjunctival redness that is considered to be due to active (inflammatory phase) GO, chemosis, and inflammation of caruncle or plica. The sum of these points is the total score, with 0 indicating no clinical activity and 7 indicating the most severe clinical activity.
| units on a scale | Placebo | Teprotumumab |
|---|---|---|
| Overall Average Change From Baseline in CAS to Week 24 (MMRM) | -1.85 ± 0.172 | -3.43 ± 0.181 |
The GO-QOL is a 16-item self-administered questionnaire used to assess the perceived effects of TED by the participants on their daily physical and psychosocial functioning. Two subscales of the 16-question GO-QOL have been defined: Visual Functioning and Appearance, with 8 questions comprising each subscale. Transformed Visual Functioning score is the sum of scores from following 8 questions to a scale of 0 (worst health) to 100 (best health): bicycling, driving, moving around the house, walking outdoors, reading, watching television (TV), hobby or pastime, feel hindered.
| units on a scale | Placebo | Teprotumumab |
|---|---|---|
| Overall Average Change From Baseline in GO-QOL Scale - Visual Functioning to Week 24 (MMRM) | 7.51 ± 2.646 | 21.67 ± 2.891 |
The GO-QOL is a 16-item self-administered questionnaire used to assess the perceived effects of TED by the participants on their daily physical and psychosocial functioning. Two subscales of the 16-question GO-QOL have been defined: Visual Functioning and Appearance, with 8 questions comprising each subscale. Transformed Appearance score is the sum of scores from the following 8 questions to a scale of 0 (worst health) to 100 (best health): feel appearance has changed, feel being stared at, feel people react unpleasantly, influence on self-confidence, feel socially isolated, influence on making friends, appear less often on photos, try to mask changes in appearance.
| units on a scale | Placebo | Teprotumumab |
|---|---|---|
| Overall Average Change From Baseline in GO-QOL Scale - Appearance to Week 24 (MMRM) | 6.60 ± 2.656 | 12.92 ± 2.836 |
Collected over Up to Week 72. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Safety Population: Placebo | 0/44 (0%) | 1/44 (2.3%) | 21/44 (47.7%) |
| Safety Population: Teprotumumab | 0/43 (0%) | 5/43 (11.6%) | 25/43 (58.1%) |
| Event | Safety Population: Placebo | Safety Population: Teprotumumab |
|---|---|---|
| DiarrheaGastrointestinal disorders | 0/44 | 1/43 |
| Inflammatory bowel diseaseGastrointestinal disorders | 0/44 | 1/43 |
| Escherichia sepsisInfections and infestations | 0/44 | 1/43 |
| Hashimoto's encephalopathyNervous system disorders | 0/44 | 1/43 |
| Urinary retentionRenal and urinary disorders | 0/44 | 1/43 |
| Optic neuropathyEye disorders | 1/44 | 0/43 |
| Event | Safety Population: Placebo | Safety Population: Teprotumumab |
|---|---|---|
| NauseaGastrointestinal disorders | 4/44 | 8/43 |
| Muscle spasmsMusculoskeletal and connective tissue disorders | 2/44 | 8/43 |
| FatigueGeneral disorders | 6/44 | 3/43 |
| DiarrhoeaGastrointestinal disorders | 2/44 | 5/43 |
| HyperglycaemiaMetabolism and nutrition disorders | 2/44 | 5/43 |
| Upper respiratory tract infectionInfections and infestations | 4/44 | 0/43 |
| DizzinessNervous system disorders | 4/44 | 0/43 |
| RashSkin and subcutaneous tissue disorders | 4/44 | 3/43 |
| Weight decreasedInvestigations | 0/44 | 3/43 |
| DysgeusiaNervous system disorders | 0/44 | 3/43 |
| Age, Continuous(years) | Placebo | Teprotumumab | Total |
|---|---|---|---|
| Mean | 54.1 ± 12.87 | 51.7 ± 10.78 | 52.9 ± 11.90 |
| Sex: Female, Male(Participants) | Placebo | Teprotumumab | Total |
|---|---|---|---|
| Female | 36 | 28 | 64 |
| Male | 9 | 14 | 23 |
Plan to share: Undecided
Ran from Jul 2013 to primary completion in Mar 2016, 32 months.
Results were first posted in Aug 2017, 1 year 5 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Teprotumumab